Equities

Viaderma Inc

VDRM:PKC

Viaderma Inc

Actions
  • Price (USD)0.0069
  • Today's Change0.000 / 2.22%
  • Shares traded1.55m
  • 1 Year change-35.15%
  • Beta-0.3728
Data delayed at least 15 minutes, as of May 31 2024 20:52 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ViaDerma, Inc. is a specialty pharmaceutical company engaged in bringing new products to market and licensing its transdermal drug delivery technology solutions. The Company’s lead product is a topical antibiotic, which is focused on being sold under the brand name Vitastem. In addition to licensing its proprietary transdermal technologies, its lead product, Vitastem, is available for treating multiple skin conditions and ailments. The Company also has products in development in fields, such as anti-aging skin care, pain management, hair-loss, and toenail fungus. The products are based on a delivery system technology that allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy. The Company’s products are sold to local medical practitioners and patients in clinics primarily in the Los Angeles, California area. The Company’s subsidiary is ViaDerma, II Inc.

  • Revenue in USD (TTM)17.80m
  • Net income in USD2.31m
  • Incorporated2010
  • Employees75.00
  • Location
    Viaderma Inc4640 Admiralty Way Ste 500MARINA DEL REY 90292-6636United StatesUSA
  • Phone+1 (310) 496-5744
  • Fax+1 (310) 943-1457
  • Websitehttp://www.viadermalicensing.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Protext Mobility Inc750.00-2.21m7.91m4.00------10,549.47-0.4692-0.46920.00001-0.01020.0405-------9,400.97-1,587.94----86.67-530.19-232,392.00-17,498.830.0002-1.36-----93.98-63.0927.35------
Molecular Templates Inc31.76m-18.40m8.03m62.00--1.12--0.2529-4.36-4.365.981.090.6014--19.55512,306.40-34.83-51.78-54.80-73.14-----57.92-228.33---52.110.00--190.1033.9691.24---48.87--
GT Biopharma Inc0.00-9.64m8.09m2.00--0.9748-----7.04-7.040.003.850.00----0.00-64.24-205.36-90.39--------------0.00------63.62------
Endexx Corp4.64m6.93m8.15m--1.21--1.371.760.01330.01330.0091-0.02550.67734.3713.54--86.51------28.73--127.74--0.0664------228.66--28.26------
Odonate Inc0.00-102.07m8.33m137.00--307.35-----13.59-13.590.009.270.00----0.00-66.98-58.36-83.00-65.14------------0.00-------12.99------
BioCardia Inc468.00k-10.34m8.41m16.00------17.97-0.4692-0.46920.0209-0.08480.0954--4.4429,250.00-210.81-107.34-1,190.90-154.17-----2,208.76-1,779.24---------64.72-5.262.82---28.89--
BioRestorative Therapies Inc145.80k-14.42m8.46m11.00--0.5101--58.04-3.54-3.540.03462.450.01--8.2613,254.55-99.26-199.86-104.68-334.04-----9,887.16-19,887.03----0.00--21.705.6122.06--67.77--
Viaderma Inc17.80m2.31m8.51m75.000.00040.000031.570.478216.8416.84129.62255.590.412624.691.21237,331.305.36--6.53--28.90--12.99--2.075.660.1718---29.15---40.70------
Energy Finders Inc4.06m-2.92m8.61m46.00------2.12-0.272-0.2721.523.04------88,304.35--------27.45---71.79--0.6706-12.570.564--------------
ABVC Biopharma Inc25.37k-12.62m8.62m16.00--1.09--339.67-2.37-2.370.00430.72840.002--0.06731,585.63-103.15-103.38-189.31-231.54-854.2076.25-51,218.29-2,019.89---3.190.1853---84.2885.3935.97------
Weed Inc0.00-5.19k8.70m2.00--80.95222.15---0.00001-0.000010.000.00090.00----0.00-0.4942-385.93-9.56-822.37-----------23.030.5461------97.93---59.13--
Shuttle Pharmaceuticals Holdings Inc0.00-7.35m8.92m8.00--3.23-----0.4739-0.47390.000.16420.00----0.00-96.75---119.37-------------5.280.2542-------112.71------
Notable Labs Ltd311.00k-12.39m9.02m16.00--0.7811--29.00-2.31-2.310.06221.280.0142----19,437.50-56.70-52.02-74.10-62.0937.3060.19-3,984.24-3,636.93----0.0271---52.89-11.9365.13---50.69--
Oragenics Inc20.63k-20.26m9.05m5.00--8.77--438.73-7.98-7.980.00790.58590.0026----4,126.00-258.71-97.60-312.34-106.24-----98,214.93-36,169.75----0.0461---71.37---44.56--51.64--
Cannapharmarx Inc0.003.69m9.14m21.001.71--2.40--0.00810.00810.00-0.0280.00----0.0042.99-131.06------------0.0034-1.02--------143.24------
Data as of May 31 2024. Currency figures normalised to Viaderma Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.